Documentation for medical weight-loss programs: GLP-1 consents grounded in current FDA labeling — boxed warnings, compounded-medication disclosures and honest investigational language where it applies.
Everything a medical weight-loss program signs: three medication consents current to FDA labeling (boxed warnings included), a weight-loss intake with eating-disorder and MEN2 screens, and a patient education sheet..
Complete semaglutide consent with the thyroid C-cell boxed warning, pancreatitis and gallbladder disclosures, and an honest compounded-semaglutide section..
Tirzepatide-specific consent including the oral-contraceptive interaction and dose-escalation expectations most templates miss..
The honest Retatrutide consent: a prominent 'Investigational — not FDA-approved' section with its own acknowledgment and initials line, plus GLP-family risk language..
Join the launch list for 25% off your first order.